Most women with advanced metastatic breast cancer appear to use their pain medications correctly, researchers concluded after conducting a study involving 53 individuals. Investigators looked at electronic diaries that were kept by participants, who made entries 6 times daily for 2 weeks. Among the results:
- Patients’ average pain level and whether their pain was better or worse than usual at the time dictated the likelihood of taking medication.
- Patients with moderate/high pain were more likely than those with low pain to be prescribed and take analgesics.
- Those with moderate/high pain tended not to vary their medication use based on fluctuating pain.
- Patients with low pain tended to increase their medication use at times when their pain was higher than usual.
- They were less likely than patients who typically experienced higher levels of pain to use medication.
The authors noted that providers should be attuned to individual factors impacting pain.
Stephenson E, DeLongis A, Bruel B, Badr H. Outpatient pain medication use: an electronic daily diary study in metastatic breast cancer. [Published online ahead of print December 5, 2017]. J Pain Symptom Manage. doi:10.1016/j.jpainsymman.2017.11.032.
This Week's Must Reads
Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.
PFS better with trofosfamide than doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomas, Hartman JT et al. ASCO 2018, Abstract 11507.
In GIST, KIT inhibitor may be of benefit in all post-imatinib lines of therapy, George S et al. ASCO 2018. Abstract 11511.
Sunitinib with regorafenib falls short for metastatic GIST, Serrano C et al. ASCO 2018 Abstract 11510.
Trabectedin extended PFS in advanced liposarcoma, Le Cesne A et al. ASCO 2018. Abstract 11508.
Must Reads in Breast Cancer
Study could clarify CTC-based staging of metastatic breast cancer , Davis A et al. ASCO 2018 Poster 1019.
Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer, Baselga et al. ASCO Abstract LBA1006.
Brain met outcomes similar for NSCLC, breast cancer patients, Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Ketorolac during primary breast cancer surgery bettered diclofenac, Desmedt C et al. J Natl Cancer Inst. 2018 Apr 30. doi: 10.1093/jnci/djy042.
FDA Approves Lynparza for Certain Types of BC, FDA news release; 2018 Jan 12